Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-12-20
2005-12-20
Jiang, Shaojia Anna (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S211060, C514S211050, C514S211040, C514S211030, C514S317000, C514S315000, C514S277000
Reexamination Certificate
active
06977252
ABSTRACT:
The present invention relates to use of compounds represented by the following general formula [1] or salts or prodrugs thereof:[where R1represents hydrogen atom or lower alkoxy group; R2represents hydrogen atom, lower alkoxy group, optionally substituted phenyl group,(where R3represents acyl group); X represents —CO— or —CH2—; and n-represents 1 or 2], as drugs for overcoming a resistance to anticancer drugs or drugs for enhancing an effect of anticancer drugs. The compounds represented by the general formula [1] have not only a function of overcoming the resistance to various anticancer drugs but also a function of enhancing the effect of various anticancer drugs to anticancer-drug sensitive cells. Thus, these compounds have excellent effects on resistant cells and also on sensitive cells, and in particular effective in the treatment of a cancer having an acquired resistance to an anticancer drug.
REFERENCES:
patent: 5416066 (1995-05-01), Kaneko et al.
patent: 5643909 (1997-07-01), Pfister et al.
patent: 5654304 (1997-08-01), Pfister et al.
patent: 5700826 (1997-12-01), Mjalli et al.
patent: 57009712 (1982-01-01), None
patent: 5-271208 (1993-10-01), None
patent: 2000-63287 (2000-02-01), None
patent: 92/12148 (1992-07-01), None
Yan et al. “Increased sensitivity to anti-leukemia drugs by application of cyclosporin A and diltiazem”, Shanghai Yixue (1998), 21(1), 10-13.
Timcheva et al. Dokladi na Bulgarskata Akademiya na Naukite (1997), 50(5), 137-140.
Hardman et al. “Goodman & Gilman's The Pharmacological Basis of Therapeutics” (9th ed, 1996) p. 51 and 57-58.
Trisha Gura, Science, vol. 278, Nov., 1997, p. 1041-1042.
Bull, “An Introduction to Physical Biochemistry” 1964, F.A. Davis Co. p. 103.
M. Baba et al., “Relationship Between Multidrug Resistant Gene Expression and Multidrug Resistant-Reversing Effect of MS-209 in Various Tumor Cells,” Cancer Chemother. Pharmacol. 36:361-367 (1995).
A. Bakka et al., “Resistance Against cis-Dichlorodiammineplatinum in Cultured Cells with a High Content of Mellothionein,” Toxicol. Appl. Pharmacol. 61:215-226 (1981).
Y. Chuman et al., “Characterization of the ATP-Dependent LTC4Transporter in Cisplatin-Resistant Human KB Cells,” Biochem. Biophys. Res. Comm. 226:158-165 (1996).
S.P.C Cole et al., “Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line,” Science 258:1650-1654 (1992).
R-I Fujii et al., “Active Efflux System for Cisplatin in Cisplatin-Resistant Human KB Cells,” Jpn. J. Cancer Res. 85:426-433 (1994).
Y. Fujiwara et al., “Determinants of Drug Response in a Cisplatin-Resistant Human Lung Cancer Cell Line,” Jpn. J. Cancer Res. 81:527-535 (1990).
D.P. Gately et al., “Cellular Accumulation of the Anticancer Agent Cisplatin: A Review,” Br. J. Cancer 67:1171-1176 (1993).
K. Hamaguchi et al., “Cross-Resistance to Diverse Drugs is Associated with Primary Cisplatin Resistance in Ovarian Cancer Cell Lines,” Cancer Res. 53:5225-5232 (1993).
N. Kaneko, “New 1,4-Benzothiazepine Derivative, K201, Demonstrates Cardioprotective Effects Against Sudden Cardiac Cell Death and Intracellular Calcium Blocking Action,” Drug. Dev. Res. 33:429-438 (1994).
S. Kondo et al., “Combination Therapy with Cisplatin and Nifedipine Inducing Apoptosis in Multidrug-Resistant Human Glioblastoma Cells,” J. Neurosurg. 82:469-474 (1995).
Y. Kondo et al., “Metallothionein Null Cells have Increased Sensitivity to Anticancer Drugs,” Cancer Res. 55:2021-2023 (1995.
K. Nakagawa et al., “Levels of Glutathione S Transferase π mRNA in Human Lung Cancer Cell Lines Correlate with the Resistance to Cisplatin and Carboplatin,” Jpn. J. Cancer Res. 79:301-304 (1988).
K. Nakagawa et al., “Glutathione-S-Transferase π as a Determinant of Drug Resistance in Transfectant Cell Lines,” J. Biol. Chem. 265:4296-4301 (1990).
J.M. Onoda et al., “In vivo Characterization of Combination Antitumor Chemotherapy with Calcium Channel Blockers andcis-Diamminedichloroplatinum (II),” Cancer Res. 49:2844-2850 (1989).
E. Reed et al., “Platinum-DNA Adduct in Leukocyte DNA of a Cohort of 49 Patients with 24 Different Types of Malignancies,” Cancer Res. 53:3694-3699 (1993).
W. Sato et al., “Reversal of Multidrug Resistance by a Novel Quinoline Derivative, MS-209,” Cancer Chemother. Pharmacol. 35:271-277 (1995).
K.J. Scanlon et al., “Cisplatin Resistance in Human Cancers,” Pharmacol. Ther. 52:385-406 (1991).
T. Tsuruo et al., “Overcoming of Vincristine Resistance in P388 Leukemia in vivo and in vitro Through Enhanced Cytotoxicity of Vincristine and Vinblastine by Verapamil,” Cancer Res. 41:1967-1972 (1981).
C.R. Wolf et al., “The Role of Glutathione in Determining the Response of Normal and Tumour Cells to Anticancer Drugs,” Biochem. Soc. Transact. 15:728-730 (1987).
K. Yusa et al., “Reversal Mechanism of Multidrug Resistance by Verapamil: Direct Binding of Verapamil to P-Glycoprotein on Specific Sites and Transport of Verapamil Outward Across the Plasma Membrane of K562/ADM Cells,” Cancer Res. 49:5002-5006 (1989).
M. Morita et al., “Ca channel blocking activity of JTV-519, a novel protective drug to cytotoxicity,” Neuroscience Research Supplement No. 22, 1998, p. S65 XP001154969, 21st Annual Meeting of the Japan Neuroscience Society and the First Joint Meeting of the Japan Neuroscience Society and the Japanese Society for Neurochemistry, Tokyo, Japan, Sep. 21-23, 1998.
T. Nakamura et al., “Reversal of Cisplatin Resistance by the 1,4-Benzothiazepine Derivative, JTV-519,” Jpn. J. Cancer Res. 92;597-602, Jun. 2001.
J.M. Onoda et al., “In Vivo Characterization of Combination of Antitumor Chemotherapy with Calcium Channel Blockers and cis-Diamminechloroplatinum (II),” Cancer Research 49(11):2844-2850, 1989.
T. Tsuruo et al., “Potentiation of antitumor agents by calcium channel blockers with special reference to cross-resistance patterns,” Cancer Chemother. Pharmacol. 15:16-19, 1985.
Noboru Kaneko, “New 1,4-Benzothiazepine Derivative, K201, Demonstrates Cardioprotective Effects Against Sudden Cardiac Cell Death and Intracellular Calcium Blocking Action,” Drug Development Research 33:429-438 (1994).
Noboru Kaneko et al., “Inhibition of annexin V-dependent Ca2+movement in large unilamellar vesicles by K201, a new 1,4-benzothiazepine derivative,” Elsevier Science B.V., Biochimica Et Biophysica Acta (BBA), retrieved Jan. 20, 1997; revised May 20, 1997; accepted May 26, 1997.
Kaneko Noboru
Nakamura Takashi
Nishio Kazuhito
Jiang Shaojia Anna
Noboru Kaneko
Ostrolenk Faber Gerb & Soffen, LLP
LandOfFree
Use of 1,4-benzothiazepine derivatives as drugs for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of 1,4-benzothiazepine derivatives as drugs for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of 1,4-benzothiazepine derivatives as drugs for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3505891